Axa’s Albany Molecular Research Inc AMRI Stock Holding History

Axa’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-5,000	Closed	-$81K	–	1525
2014 Q4	$81K	Buy	+5,000	New	+$91.8K	﹤0.01%	1331
2014 Q2	–	Sell	-55,600	Closed	-$1.03M	–	1467
2014 Q1	$1.03M	Sell	55,600 -11,300	-17%	-$156K	﹤0.01%	911
2013 Q4	$674K	Buy	66,900 +3,700	+6%	+$44.7K	﹤0.01%	1001
2013 Q3	$815K	Buy	63,200 +9,600	+18%	+$118K	﹤0.01%	909
2013 Q2	$636K	Buy	+53,600	New	+$581K	﹤0.01%	923

Other funds holding AMRI

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PIP

Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VNIM

Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return

OWP

Obermeyer Wealth Partners Aspen, Colorado $2.17B AUM 19.33% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

EWM

Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Axa's AMRI Position: Q1 2015 in Review

Axa sold out of Albany Molecular Research Inc (AMRI) in Q1 2015, closing a stake of 5,000 shares — an estimated $81K sold.

Axa first reported a position in AMRI in Q2 2013 and held it in 5 quarters. The position peaked at $1.03M in Q1 2014. 131 funds tracked by Wall St. Rank hold AMRI as of Q1 2015.

Axa reported no remaining Albany Molecular Research Inc position as of Q1 2015 after selling out during the quarter.
Axa sold 5,000 Albany Molecular Research Inc shares in Q1 2015, an estimated $81K.
Axa first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 5 quarters.
Axa's Albany Molecular Research Inc position peaked at $1.03M in Q1 2014.
131 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q1 2015.

Based on Axa's 13F filing for Q1 2015, filed 13 May 2015.